Hepion Pharmaceuticals (HEPA)
(Delayed Data from NSDQ)
$0.76 USD
-0.06 (-7.20%)
Updated Aug 23, 2024 03:54 PM ET
After-Market: $0.74 -0.02 (-2.63%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Hepion Pharmaceuticals, Inc. [HEPA]
Reports for Purchase
Showing records 1 - 20 ( 52 total )
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
AMBITION trial shows positive biomarker data
Provider: Edison Investment Research Limited
Analyst: Research Department
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
First data on liver enzymes encouraging
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Recapitalizing Financing Completed - Lowering Price Target
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Final Program for Our Fourth Annual Virtual NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are updating coverage of our Healthcare sector to better allocate our research resources in
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Most Explored Anti-Fibrotic in NASH, Transferring Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Hepion Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase I clinical trial nearing completion
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N